Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;20(5):503-7.
doi: 10.1016/j.parkreldis.2014.02.001. Epub 2014 Feb 13.

Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status

Sarah E Monsell  1 , Lilah M Besser  2 , Katherine B Heller  2 , Harvey Checkoway  3 , Irene Litvan  4 , Walter A Kukull  2
Affiliations

Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status

Sarah E Monsell et al. Parkinsonism Relat Disord. 2014 May.

Abstract

Background: Apolipoprotein (APOE) e4 allele status has been linked to clinical presentation and progression in Alzheimer's disease; however, evidence for a role of APOE e4 in Parkinson's disease (PD) remains largely inconclusive. In this analysis we explored potential significant associations between APOE e4 allele status and characteristics of clinical presentation in patients with PD.

Methods: Data came from 424 subjects evaluated using the Uniform Data Set (UDS) assessment collected by the National Alzheimer's Coordinating Center. Subjects had a known year of diagnosis of PD and experienced change in motor function prior to any change in cognition. Linear and logistic regression were used to model the association between APOE e4 carrier status and clinical characteristics including measures of cognitive decline and motor and neuropsychiatric symptoms. Amyloid burden was also evaluated for a subset of patients who died and consented to autopsy.

Results: Odds of dementia were higher in APOE e4 carriers (OR = 5.15), and, on average, APOE e4 carriers scored two points worse on tests of episodic memory and the Clinical Dementia Rating Sum of Boxes assessment. There was little evidence to support an association between e4 carrier status and severity of motor features, and, of the four neuropsychiatric symptoms evaluated, only presence of hallucinations was significantly associated with APOE e4 carrier status (OR = 5.29). Neuropathology data revealed higher frequencies of neuritic and diffuse amyloid plaques in APOE e4 carriers compared to non-carriers.

Conclusions: APOE e4 allele status is associated with dementia and severity of Alzheimer's disease pathologic features in PD.

Keywords: APOE; Clinical symptoms; Neuropathology; Parkinson's disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of neurofibrillary tangles and neuritic plaques by APOE e4 carrier status
See this image and copyright information in PMC

References

    1. Reiman EM. In this issue: genetics, cholesterol, and the risk of Alzheimer’s disease. J Clin Psychiatry. 2005;66:938–9. - PubMed
    1. Cosentino S, Scarmeas N, Helzner E, Glymour MM, Brandt J, Albert M, et al. APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology. 2008;70:1842–9. - PMC - PubMed
    1. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer’s disease. Neuron. 2009;63:287–303. - PMC - PubMed
    1. Campbell MC, Markham J, Flores H, Hartlein JM, Goate AM, Cairns NJ, et al. Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. Neurology. 2013;81:520–7. - PMC - PubMed
    1. Federoff M, Jimenez-Rolando B, Nalls MA, Singleton AB. A large study reveals no association between APOE and Parkinson’s disease. Neurobiol Dis. 2012;46:389–92. - PMC - PubMed

Publication types

MeSH terms

Substances